
At ACAAI 2026, Jennifer Priessnitz, MD presented data which found omalizumab had the highest anaphylaxis reporting proportion among 7 respiratory biologics.

Jennifer K. Priessnitz, MD, a resident at Macon & Joan Brock Virginia Health Sciences at Old Dominion University.